# Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

> **NCT03215810** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 20 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Metastatic Non-small Cell Lung Cancer
- Squamous Cell Carcinoma
- Advanced NSCLC
- Adenosquamous Carcinoma
- Adenocarcinomas

## Interventions

- **PROCEDURE:** Tumor-infiltrating Lymphocytes (TIL)
- **DRUG:** Nivolumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **OTHER:** Tumor-infiltrating Lymphocyte Therapy
- **DRUG:** Interleukin-2 (IL2)

## Key facts

- **NCT ID:** NCT03215810
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-11
- **Primary completion:** 2021-02-13
- **Final completion:** 2023-06-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-07-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03215810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03215810, "Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03215810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*